Track SABS and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
SAB Biotherapeutics Inc
777 W 41st St., Miami Beach, FL, United States, 33140
IPO
2021
Employees
86
Industry
Biotechnology
Sector
Healthcare
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q4 20230+3
3
Analyst Ratings
1 analysts covering
Buy100%recommend buy
Buy
1
Hold
0
Sell
0